Hopkins Biotech Podcast

Hopkins Biotech Podcast
  • 5.0 (10)
  • Life Sciences

Illuminating life science career opportunities outside of academia through the experiences of those who have been there before.

  1. 10/01/2025

    Sickle Cell Disease: New Wave of Gene Therapies

    Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future.

  2. 01/05/2024

    Roivant: Reinventing the Paradigm of Conventional Drug Development

    Roivant Pharma is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for the company. He also informs Roivant’s view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio.  Mayukh joined Roivant in 2015 and previously served as President of Roivant Pharma and as Chief Business Officer. Programs that he has in-licensed or acquired for Roivant have produced all 10 of Roivant’s positive Phase 3 studies and have garnered 6 FDA approvals. Before joining Roivant, Mayukh was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. He earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT. Hosted by Joe Varriale.

  3. 12/18/2023

    Public Relations and Scientific Communications for Biotechnology with Ignacio Guerrero-Ros

    Dr. Ignacio Guerrero-Ros is an immunologist turned scientific communicator and biotech media innovator. Currently, he is an Assistant Vice President at Russo Partners, providing public and investor relations services to clients in the healthcare and technology industries. Originally from Spain, Ignacio earned his PhD in Immunology from Albert Einstein College of Medicine. Ignacio embraces the Hopkins Biotech Podcast's mission of the pursuit of alternative careers for PhD holders.  In this episode, we discuss his ideas for how to find success beyond grad school and how he found a passion for science communication. Hosted by Joe Varriale.

  4. 11/01/2023

    What You Should Know About the Biotech Job Market in 2023 with Carina Clingman

    Carina Clingman, Ph.D., is the Founder and CEO of Recruitomics Consulting, a niche talent acquisition and talent strategy firm specializing in biotech startups. She recently founded The Collaboratory Career Hub to help biotech job seekers find confidence and success in their job search. If you're exploring careers in biotech, join the free Collaboratory Slack Community to work directly with Carina and her team.  In this episode, we discuss the state of the biotech job market and offer advice to job seekers and those considering careers in the biotech industry. Hosted by Joe Varriale.

  5. 10/09/2023

    Antibody-Drug Conjugates: Targeting Cancer Where it is Vulnerable with David Dornan of Elevation Oncology

    About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology, a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multiple therapeutic modalities targeting cancer susceptibilities and modulating the immune system to translate into meaningful therapeutic interventions for patients. As Chief Scientific Officer, he is responsible for scientific strategy and building of the company’s portfolio in targeted immunotherapies. Before leading these efforts at Elevation Oncology, David was the CSO at Bolt Biotherapeutics. Prior to this, he was the head of Oncology Research at Gilead. David began his career at Genentech, where he spent 10 years serving in positions of increasing responsibility and played key roles in target discovery and validation, as well as translational research programs. David received his Ph.D. from the University of Dundee in Molecular Oncology and Biochemistry and completed a postdoctoral fellowship at Genentech. In this episode, we discuss Elevation’s ongoing clinical development of antibody-drug conjugate molecules to treat cancer and David’s wealth of experience in biotech and pharma. Hosted by Joe Varriale.

  6. 08/14/2023

    Boston Biotech Series: Standing out in the Competitive Recruiting Process for Early Stage Biotech

    Emily Gransky is the Vice President of Recruiting at RA Ventures (RAVen). RAVen is the early-stage venture arm of the multi-stage investment firm RA Capital. In this role, Emily works closely with senior leaders, venture partners, and managing directors within the Venture Team at RA Capital and within RAVen. Her primary responsibility is leading and executing full-cycle recruiting across all newcos and portfolio companies. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio, leading hiring across all functions and building out systems to support that growth. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition at bluebird bio. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Emily received her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. In this episode, we discuss crucial factors that drive the hiring process for start-up biotech companies, and how to stand out as a candidate while recruiting in this competitive environment.  Hosted by Joe Varriale.

  7. 07/17/2023

    Boston Biotech Series: Building a Drug Development Platform on New Biology with Isaac Klein of Dewpoint Therapeutics

    Dr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics. Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines targeting biomolecular condensates. Prior to joining Dewpoint, Isaac was on the faculty at the Dana Farber Cancer Institute and Harvard Medical School, as well as a scientist at the Whitehead Institute of MIT. He holds a Ph.D. in Biology from The Rockefeller University and an MD from Weill Cornell Medical College. He trained in Internal Medicine at the Brigham and Women’s Hospital of Harvard Medical School and in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. In 2022, Isaac was named one of Endpoints News 20 under 40 in Biopharma. Hosted by Joe Varriale.

  8. 04/17/2023

    Boston Biotech Series: Facilitating Start-up Company Formation with Adam Jenkins of Biolabs

    Dr. Adam Jenkins is the Regional Site Director for the Massachusetts sites of Biolabs. BioLabs is an international, membership-based network of shared lab and office facilities located in key biotech innovation clusters. Since 2009, over 230 companies have launched from Biolabs facilities, and those member companies have collectively raised more than 1 billion dollars in private financing. With a growing number of sites across the globe, Biolabs is enabling company formation and promoting the biotech revolution. Prior to joining Biolabs in 2022, Adam worked at Biogen for seven years in various data science roles and eventually held the title of Associate Director of Corporate Strategy and Partnerships for Insights and Analytics. Adam holds a Ph.D. in Genomics from Boston College. In this episode, we discuss Biolabs’ unique business model that facilitates biotech company founding, the influence of biotech hubs, and the future of data science in biotech.  Hosted by Joe Varriale.

See All (85)

Ratings & Reviews

5
out of 5
10 Ratings

About

Illuminating life science career opportunities outside of academia through the experiences of those who have been there before.

Information

  • Creator
    Hopkins Biotech Podcast
  • Years Active
    2020 - 2025
  • Episodes
    85
  • Rating
    Clean
  • Copyright
    © 2026 Hopkins Biotech Podcast
  • Show Website
    Hopkins Biotech Podcast